BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
January 22 2020 - 6:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology
company specializing in targeted immunotherapies for advanced
breast cancer, announced today that it will present at the
“Frontiers in Academic Pathology” symposium, hosted by the Icahn
School of Medicine at Mount Sinai, to be held on Friday, January
31, 2020 at The New York Academy of Medicine, 1216 Fifth Avenue in
New York. The symposium focus will include molecular
biomarkers, experimental diagnostics and liquid biopsies, all of
which factor heavily in the development of BriaCell’s companion
diagnostics under development, including BriaCell’s HLA-matching
hypothesis and recently-announced Grade I/II biomarkers.
Dr. Bill Williams, BriaCell’s President &
CEO, will be presenting BriaCell’s unique and effective
immunotherapy approach at the conference, focusing on the
biomarkers noted to date in determining clinical benefit in
advanced stage breast cancer.
Following the presentation, a copy will be posted
on https://briacell.com/investor-relations/presentations/.
“We are grateful to Icahn School of Medicine at
Mount Sinai for their validation in inviting us to share our
targeted immunotherapy approach with oncologists and scientists,”
stated Dr. Bill Williams. “As we are advancing the development of
our novel personalized, off-the-shelf immunotherapy, we are
learning more about the clinical application of molecular and
pathologic biomarkers to guide us in the treatment of advanced
breast cancer patients. This approach will allow us to target
therapies to patients most likely to clinically benefit from the
treatment.”
“As we develop of our novel personalized
immunotherapy for advanced breast cancer patients, we are
discovering that our technology and biomarkers may be applicable to
a number of tumor types. The key is patient selection based on the
molecular, cellular and pathologic characteristics of the
cancer. We will share these insights with the attendees of
this ground-breaking meeting,” Dr. Williams added.
About Frontiers in Academic Pathology:
Transplant and Therapeutic Pathology
The Council for Continuing Medical Education
(CME) Accredited course, hosted by Icahn School of Medicine at
Mount Sinai, is intended for Pathologists, Oncologists, Transplant
Surgeons, Translational and Basic Researches, both in practice and
in training, as well as researchers with an interest in Prostate
Carcinogenesis and Progression.
The course will address critical areas in
transplantation and cell-based therapeutics. At the
conclusion of the activity, participants will be able to: 1)
Describe the use and limitations of diagnostic modalities and
biomarkers in the management of patients undergoing cell-based and
organ transplantation. 2) Describe recent and developing approaches
toward HLA typing. 3) Describe novel clinical applications of
cell-based diagnostics and treatments. 4) Describe developing
legislation, regulatory and ethical guidelines for the use of human
cells or tissue in implantation, transplantation, or transfer into
a human recipient.
For conference information, please Email:
cme@mssm.edu.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Sep 2023 to Sep 2024